Editorial: 5-Amino-1MQ Is a Promising Mouse Drug Being Sold to Humans

I want to say this plainly because the marketing around 5-amino-1MQ rarely does: the compound works, in mice. It inhibits NNMT, it lowers a specific enzymatic bottleneck tied to fat cell metabolism, and in diet-induced obese mice it produces measurable weight and adiposity changes (Neelakantan et al., 2018). That is a real finding. It is also, as of this writing, the ceiling of what the human-relevant evidence base supports.

What is actually being sold versus what was actually studied

Every mechanistic paper on 5-amino-1MQ that HealthRX.com has reviewed was conducted in mice, rats, or isolated cells. The enzyme target, NNMT, is genuinely interesting: it sits at a metabolic crossroads involving NAD+ availability, methyl group donation, and adipocyte energy handling (Kraus et al., 2021; Ye et al., 2021). NNMT inhibition has been shown to reverse high-fat-diet-induced obesity specifically in mice (Neelakantan et al., 2018) and to mitigate obesity-related metabolic dysfunction in more recent rodent work (Cordoba-Chacon et al., 2024). A 2024 review frames NNMT as a "novel therapeutic target" for metabolic syndrome (Kannt & Wohlfart, 2024), and that word, target, is doing honest work. A target is a hypothesis for drug development, not a finished drug.

What does not exist, in any database HealthRX.com can locate, is a controlled human trial of 5-amino-1MQ measuring weight loss, body composition, glucose control, or safety outcomes in people. Pharmacokinetic characterization has been done in rat plasma (Cheng et al., 2021), which tells you something about oral absorption in rodents and nothing about human dosing, human liver metabolism, or human tolerability. Our companion pages on oral bioavailability and dosing claims walk through why that rat pharmacokinetic data cannot be scaled into a human dose without unverified assumptions.

Why "it inhibits the right enzyme" is not the same as "it works in you"

The pharmacology community has spent real effort building assays to characterize NNMT inhibitors precisely because early candidates are messy: some bind the substrate site, some are allosteric, some are membrane-permeable and some are not (Neelakantan et al., 2016; Policarpo et al., 2019). 5-amino-1MQ was selected in early screens specifically for membrane permeability and selectivity over other methyltransferases (Neelakantan et al., 2018). That is good medicinal chemistry. It says nothing about whether the compound survives first-pass hepatic metabolism in a human, reaches adipose tissue at an effective concentration, or does so without off-target effects across weeks or months of use, which is the actual timescale anyone buying it for weight loss intends to use it.

Newer chemical scaffolds, including tricyclic inhibitors (Policarpo et al., 2022) and macrocyclic peptide-based allosteric inhibitors (Babault et al., 2021), exist precisely because the field is still optimizing for a compound worth taking into human trials. If 5-amino-1MQ itself were that compound, you would expect a Phase 1 safety trial to already be registered or published. It is not, as far as our search of PubMed indicates.

What is established, what is plausible, and what is not established

Established (rodent and cell-based evidence): NNMT inhibition alters fat metabolism markers and body weight in diet-induced obese mice (Neelakantan et al., 2018; Cordoba-Chacon et al., 2024). NNMT expression responds to glucose availability in adipocytes (Kannt et al., 2020) and is dynamically induced during beige adipogenesis (Kraus et al., 2022).

Plausible but unproven in humans: that these same mechanisms translate into meaningful fat loss, improved insulin sensitivity, or muscle-related benefit in adult humans taking oral 5-amino-1MQ at any commercially sold dose. Our weight-loss evidence page and muscle research page detail why the muscle and body-composition claims in particular outrun even the mouse data.

Not established: human safety at any dose, human pharmacokinetics, drug interactions, effects in people with existing metabolic disease, and long-term outcomes of any kind. There is also no FDA-approved use for 5-amino-1MQ, and it is not listed on the FDA's 503A bulk drug substances list for compounding, a status you can verify directly through the FDA's bulk substances page or through our FDA status page and the FDA Peptide Status Tracker, which despite the name also tracks non-peptide small molecules like this one.

A translation-gap checklist for reading any NNMT-inhibitor claim

Before treating a claim about 5-amino-1MQ as actionable, ask which box it actually falls into:

If a vendor's claim sits in the bottom two rows, ask them to name the human trial. If they cannot, the claim is marketing dressed as pharmacology.

Where does this leave someone considering it

If you are weighing 5-amino-1MQ against an FDA-approved option, the honest comparison is not close on the evidence axis, whatever it may be on convenience or cost. GLP-1 receptor agonists have large randomized human trials behind their approved indications; 5-amino-1MQ has mouse trials behind a mechanism. Our 5-amino-1MQ versus GLP-1 comparison lays out that asymmetry in more detail, and the side effects and safety page covers what little is known about tolerability from the animal literature, which is not a substitute for human safety data.

None of this means the NNMT pathway is a dead end. It means the pathway is still in the drug-development phase, not the consumer-product phase. Readers experiencing unexplained weight change, metabolic symptoms, or considering any unregulated compound alongside existing medications or conditions should talk to a physician before starting it, and anyone who develops signs of an adverse reaction after taking an unregulated compound should seek urgent medical care rather than trying to self-diagnose using rodent literature.

The gap between "inhibits the right enzyme in mice" and "safe and effective in you" is not a rounding error. It is the entire distance a compound normally travels during a clinical development program, a distance 5-amino-1MQ has not yet traveled in public, peer-reviewed form.